Robert Goodenow
President
pharmaceutical
Huya Bioscience
China
Biography
Robert Goodenow, PhD has over 25 years experience in the pharmaceutical industry, at both the executive and senior management levels, in numerous multinational pharmaceutical and biotechnology companies. His leadership roles have encompassed research and development, business development, and commercialization including market launch. He has a strong licensing track record of global and regional transactions. Most recently, Dr. Goodenow served as Chief Business Officer at Syndax Pharmaceuticals where he led the business and commercial development efforts for the Company’s epigenetic platform in oncology. Prior to this, he was Vice President of Corporate Development for Inovio Biomedical and held various senior level positions within Rhone-Poulenc Rorer, Aventis and Baxter Healthcare. Dr. Goodenow received a Ph.D. in Biophysics from Stanford University Medical School and holds an A.B. in Biochemistry from the University of California at Berkeley. He was an American Cancer Society Fellow in the Division of Biology at CALTECH.
Research Interest
pharmaceutical
